Evelo Biosciences to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
Evelo Biosciences (Nasdaq: EVLO) will host a conference call on April 29, 2021, at 8:30 a.m. ET to report its Q1 2021 financial results and discuss business highlights. The call can be accessed at 866-795-3242 for domestic and 409-937-8909 for international callers, using conference ID 5856668. Evelo is developing orally delivered medicines targeting the immune, metabolic, and neurological systems via SINTAX. It has four product candidates in development for inflammatory diseases and cancer.
- Four product candidates in clinical development for significant diseases.
- Focus on innovative orally delivered medicines targeting systemic therapeutic effects.
- None.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights.
To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 5856668. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on SINTAX™, the small intestinal axis, and to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn and video.
Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
What date will Evelo report its Q1 2021 financial results?
How can I access Evelo's conference call?
What are the main product candidates being developed by Evelo?
